Published in Br J Cancer on November 01, 1995
Stress-induced enhancement of leukocyte trafficking into sites of surgery or immune activation. Proc Natl Acad Sci U S A (2005) 1.38
Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. Br J Cancer (1996) 0.99
Platelet expression of tumour necrosis factor-alpha (TNF-alpha), TNF receptors and intercellular adhesion molecule-1 (ICAM-1) in patients with proliferative diabetic retinopathy. Clin Exp Immunol (1999) 0.98
To NFκB or not to NFκB: The Dilemma on How to Inhibit a Cancer Cell Fate Regulator. Transl Med UniSa (2012) 0.82
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem (1987) 281.19
An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A (1975) 23.42
Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon. J Immunol (1986) 8.22
Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med (1986) 6.32
Endothelial-leukocyte adhesion molecules. Annu Rev Immunol (1993) 4.96
Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis. J Immunol (1988) 3.64
High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol (1992) 2.12
Tumor necrosis factor induces apoptosis (programmed cell death) in normal endothelial cells in vitro. Am J Pathol (1991) 1.88
Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest (1993) 1.62
Circulating interleukin 6 during a continuous infusion of tumor necrosis factor and interferon gamma. J Exp Med (1989) 1.59
TNF-induced microvascular pathology: active role for platelets and importance of the LFA-1/ICAM-1 interaction. Eur Cytokine Netw (1994) 1.56
Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res (1988) 1.54
Antitumor activity of recombinant interleukin 6 in mice. J Exp Med (1990) 1.37
A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol (1988) 1.36
Inhibition of tumor cell growth by interferon-gamma is mediated by two distinct mechanisms dependent upon oxygen tension: induction of tryptophan degradation and depletion of intracellular nicotinamide adenine dinucleotide. J Clin Invest (1989) 1.34
Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons. Cancer Res (1986) 1.29
Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha). Int J Cancer (1994) 1.22
In vivo anti-tumour activity of recombinant human and murine TNF, alone and in combination with murine IFN-gamma, on a syngeneic murine melanoma. Int J Cancer (1986) 1.22
Recombinant human tumor necrosis factor-alpha: thrombus formation is a cause of anti-tumor activity. Int J Cancer (1988) 1.19
Tumor necrosis factor alpha induces apoptosis in mammary adenocarcinoma cells by an increase in intranuclear free Ca2+ concentration and DNA fragmentation. Cancer Res (1992) 1.16
The differential effects of human leukocyte pyrogen/lymphocyte-activating factor, T cell growth factor, and interferon on human natural killer activity. J Immunol (1982) 1.15
Interferon-gamma synergizes with tumor necrosis factor and with interleukin 1 and requires the presence of both monokines to induce antitumor cytotoxic activity in macrophages. J Immunol (1987) 1.15
Dissociation of TNF-alpha cytotoxic and proinflammatory activities by p55 receptor- and p75 receptor-selective TNF-alpha mutants. EMBO J (1994) 1.15
Plasminogen activators, plasminogen activator inhibitors and procoagulant analyzed in twenty human tumor cell lines. Int J Cancer (1986) 1.10
Recombinant tumor necrosis factor: species specificity for a variety of human and murine transformed cell lines. Cell Immunol (1986) 1.03
Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan. J Clin Oncol (1995) 0.92
Mechanism of antitumor activity of tumor necrosis factor alpha with hyperthermia in a tumor necrosis factor alpha-resistant tumor. J Natl Cancer Inst (1990) 0.90
Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon, and melphalan. Cancer (1994) 0.88
Therapeutic potential of tumor necrosis factor-alpha and gamma-interferon in experimental human ovarian cancer. Cancer Res (1987) 0.88
Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res (1994) 0.86
Tumor necrosis factor alpha induces early morphologic and metabolic alterations in Friend leukemia cell tumors and fibrosarcomas in mice. Int J Cancer (1988) 0.81
Effective regional therapy of experimental cancer with paralesional administration of tumour necrosis factor-alpha + interferon-gamma. Surg Oncol (1992) 0.78
High-resolution global maps of 21st-century forest cover change. Science (2013) 17.90
Inactivation of the beta-catenin gene by Wnt1-Cre-mediated deletion results in dramatic brain malformation and failure of craniofacial development. Development (2001) 9.00
Digital tomosynthesis in breast imaging. Radiology (1997) 5.82
Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA (1997) 4.49
Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med (1999) 4.41
Complete nucleotide sequence of a milk-transmitted mouse mammary tumor virus: two frameshift suppression events are required for translation of gag and pol. J Virol (1987) 4.37
Sequence, topography and protein coding potential of mouse int-2: a putative oncogene activated by mouse mammary tumour virus. EMBO J (1986) 4.08
Expression of Cre recombinase in mouse oocytes: a means to study maternal effect genes. Genesis (2000) 3.71
The cytokine network. Immunol Today (1989) 3.57
Phenobarbital-responsive nuclear translocation of the receptor CAR in induction of the CYP2B gene. Mol Cell Biol (1999) 2.93
Practice parameters for the treatment of sigmoid diverticulitis--supporting documentation. The Standards Task Force. The American Society of Colon and Rectal Surgeons. Dis Colon Rectum (2000) 2.77
Plasma concentrations after oral or intramuscular vitamin K1 in neonates. Arch Dis Child (1985) 2.69
PKCalpha regulates beta1 integrin-dependent cell motility through association and control of integrin traffic. EMBO J (1999) 2.66
Risk factors for homelessness. Epidemiol Rev (1993) 2.55
Hypocritical tosh. Br Dent J (2010) 2.48
Lifetime and five-year prevalence of homelessness in the United States: new evidence on an old debate. Am J Orthopsychiatry (1995) 2.42
Reconstitution of interleukin 2 with albumin for infusion. Lancet (1990) 2.37
Ezrin is a downstream effector of trafficking PKC-integrin complexes involved in the control of cell motility. EMBO J (2001) 2.27
A new family of lipolytic enzymes? Trends Biochem Sci (1995) 2.17
Alteration of intestinal tight junction structure and permeability by cytoskeletal contraction. Am J Physiol (1987) 2.14
Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet (1997) 2.12
Prevention of relapse in residual depression by cognitive therapy: a controlled trial. Arch Gen Psychiatry (1999) 2.12
Prophylactic treatment of postperfusion bleeding using EACA. Chest (1989) 2.09
IGF-II induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme transition. Oncogene (2001) 2.03
Strand displacement amplification and homogeneous real-time detection incorporated in a second-generation DNA probe system, BDProbeTecET. Clin Chem (1999) 2.01
How roots respond to gravity. Sci Am (1986) 1.95
Genetic structure, function and regulation of the transposable element IS21. Mol Gen Genet (1989) 1.93
The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J Clin Invest (1995) 1.91
Molecular cloning and nucleotide sequence of a full-length cDNA for human alpha enolase. Proc Natl Acad Sci U S A (1986) 1.87
Complications of smallpox vaccination. I. National survey in the United States, 1963. N Engl J Med (1967) 1.86
Measuring cytokine levels in blood. Importance of anticoagulants, processing, and storage conditions. J Immunol Methods (1992) 1.84
Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol (1997) 1.79
Amantadine small-particle aerosol: generation and delivery to man. Proc Soc Exp Biol Med (1979) 1.76
Laparoscopic complications in markedly obese urologic patients (a multi-institutional review) Urology (1996) 1.75
Developmental exposure to diethylstilbestrol elicits demethylation of estrogen-responsive lactoferrin gene in mouse uterus. Cancer Res (1997) 1.74
Zymography: a single-step staining method for quantitation of proteolytic activity on substrate gels. Anal Biochem (1997) 1.70
Public knowledge, attitudes, and beliefs about homeless people: evidence for compassion fatigue. Am J Community Psychol (1995) 1.69
Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer (1993) 1.68
Metastatic patterns in soft-tissue sarcomas. Arch Surg (1983) 1.66
A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res (1993) 1.65
T2 open reading frame from the Shope fibroma virus encodes a soluble form of the TNF receptor. Biochem Biophys Res Commun (1991) 1.64
Species specificity of ectromelia virus and vaccinia virus interferon-gamma binding proteins. Virology (1995) 1.64
Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest (1993) 1.62
Cryptosporidium parvum infection of Caco-2 cell monolayers induces an apical monolayer defect, selectively increases transmonolayer permeability, and causes epithelial cell death. Infect Immun (1994) 1.61
Epithelial cancer cell migration: a role for chemokine receptors? Cancer Res (2001) 1.61
Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids. Kidney Int (2000) 1.60
The pendent view: an additional projection to confirm the diagnosis of milk of calcium. AJR Am J Roentgenol (2001) 1.58
Central nervous system toxicity of interferon. Br J Cancer (1983) 1.58
Emergency asthma inhalers in school. Arch Dis Child (2003) 1.56
Replication and resolution of cloned poxvirus telomeres in vivo generates linear minichromosomes with intact viral hairpin termini. J Virol (1986) 1.53
Tension-free vaginal tape: outcomes among women with primary versus recurrent stress urinary incontinence. Obstet Gynecol (2002) 1.51
A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann Oncol (2008) 1.50
Predicting bacteremia in patients with sepsis syndrome. Academic Medical Center Consortium Sepsis Project Working Group. J Infect Dis (1997) 1.50
Measurement of risk for mental disorders and competence in a psychiatric epidemiologic community survey: the National Institute of Mental Health Methods for the Epidemiology of Child and Adolescent Mental Disorders (MECA) Study. Soc Psychiatry Psychiatr Epidemiol (1998) 1.50
SERP1, a serine proteinase inhibitor encoded by myxoma virus, is a secreted glycoprotein that interferes with inflammation. Virology (1993) 1.49
Activation by diverse xenochemicals of the 51-base pair phenobarbital-responsive enhancer module in the CYP2B10 gene. Mol Pharmacol (1998) 1.49
Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort. Neurology (2006) 1.47
Nuclear PtdIns(4,5)P2 assembles in a mitotically regulated particle involved in pre-mRNA splicing. J Cell Sci (2001) 1.47
Computerized mass detection for digital breast tomosynthesis directly from the projection images. Med Phys (2006) 1.46
The peptide near the C terminus regulates receptor CAR nuclear translocation induced by xenochemicals in mouse liver. Mol Cell Biol (2001) 1.46
A poxvirus-encoded uracil DNA glycosylase is essential for virus viability. J Virol (1993) 1.45
Observation of B(0)(s)-->Psi(2S)Phi and measurement of the ratio of branching fractions Beta(B(0)(s)-->Psi(2S)Phi)/Beta(B(0)(s)-->J/PsiPhi). Phys Rev Lett (2006) 1.40
Detection of alcoholism in hospitalized children and their families. Am J Dis Child (1991) 1.39
Genomic cartography of varicella-zoster virus: a complete genome-based analysis of strain variability with implications for attenuation and phenotypic differences. Virology (2006) 1.39
Translocation of Shiga toxin across polarized intestinal cells in tissue culture. Infect Immun (1996) 1.39
Survival in metastatic ocular melanoma. Cancer (1983) 1.37
Expression of tumour necrosis factor (TNF alpha) and its receptors in benign and malignant breast tissue. Int J Cancer (1994) 1.35
DNA fragmentation and cytotoxicity caused by tumor necrosis factor is enhanced by interferon-gamma. Eur J Immunol (1987) 1.34
CED-4 induces chromatin condensation in Schizosaccharomyces pombe and is inhibited by direct physical association with CED-9. Curr Biol (1997) 1.30
Cells secreting tumour necrosis factor show enhanced metastasis in nude mice. Eur J Cancer (1990) 1.30
Precision top-quark mass measurement at CDF. Phys Rev Lett (2012) 1.30
A multi-institutional analysis of laparoscopic orchidopexy. BJU Int (2001) 1.30
Telomere shortening in kidneys with age. J Am Soc Nephrol (2000) 1.29
Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons. Cancer Res (1986) 1.29
Expression and activity of MMPS and their regulators in ovarian cancer. Int J Cancer (1994) 1.27
An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancer. Eur J Cancer Clin Oncol (1988) 1.27
Viral Genome DataBase: storing and analyzing genes and proteins from complete viral genomes. Bioinformatics (2000) 1.26
A phase I study of human lymphoblastoid interferon administered by continuous intravenous infusion. Cancer Chemother Pharmacol (1982) 1.26
Poxviruses: past, present and future. Virus Res (2006) 1.26
Primary hypothyroidism associated with interferon therapy of breast cancer. Lancet (1985) 1.26
Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother-to-child transmission. Proc Natl Acad Sci U S A (1995) 1.25
Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res (1986) 1.24
Prognostic value of lymph node dissection in malignant melanoma. Arch Surg (1980) 1.24
Characterization of phenobarbital-inducible mouse Cyp2b10 gene transcription in primary hepatocytes. J Biol Chem (1996) 1.23
Measurement of the cross section for prompt isolated diphoton production using the full CDF run II data sample. Phys Rev Lett (2013) 1.22
A new family of lipolytic plant enzymes with members in rice, arabidopsis and maize. FEBS Lett (1995) 1.22
Paradoxical effects of tumour necrosis factor in experimental ovarian cancer. Int J Cancer (1989) 1.22
Inhibition of monocyte and macrophage chemotaxis by hypoxia and inflammation--a potential mechanism. Eur J Immunol (2001) 1.22
Detection and characterization of the fibroblast growth factor-related oncoprotein INT-2. Mol Cell Biol (1989) 1.21
Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int J Cancer (1997) 1.20
The genome of Shope fibroma virus, a tumorigenic poxvirus, contains a growth factor gene with sequence similarity to those encoding epidermal growth factor and transforming growth factor alpha. Mol Cell Biol (1987) 1.19
Abdominal wall hernia in autosomal dominant polycystic kidney disease. Br J Surg (1997) 1.18
The ppp(A2'p)nA and protein kinase systems in wild-type and interferon-resistant Daudi cells. Eur J Biochem (1982) 1.18
Annular tears and disc degeneration in the lumbar spine. A post-mortem study of 135 discs. J Bone Joint Surg Br (1992) 1.18
Mouse decay-accelerating factor: selective and tissue-specific induction by estrogen of the gene encoding the glycosylphosphatidylinositol-anchored form. J Immunol (1996) 1.17
A possible screening test for inherited p53-related defects based on the apoptotic response of peripheral blood lymphocytes to DNA damage. Br J Cancer (1995) 1.17
A DNA methylation site in the male-specific P450 (Cyp 2d-9) promoter and binding of the heteromeric transcription factor GABP. Mol Cell Biol (1995) 1.17